top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Dwight Gary Gilliland net worth and biography

Dwight Gilliland Biography and Net Worth

Director of Laboratory Co. of America

D. Gary Gilliland has served as a director of the Company since April 1, 2014. Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center, a research organization, in Seattle, WA since January 31, 2020. From January 2, 2015 to January 30, 2020, Dr. Gilliland previously served as President and Director of the Fred Hutchinson Cancer Research Center. Prior to that, he was the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine from October 2013 to January 2015, where he was responsible for synthesizing research and clinical-care initiatives across all medical disciplines including cancer, heart and vascular medicine, neurosciences, genetics, and pathology, to create a national model for the delivery of precise, personalized medicine. From 2009 until he joined Penn Medicine in 2013, Dr. Gilliland was Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. At Merck, Dr. Gilliland oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials that included the development of pembrolizumab (anti-PD1) for treatment of cancer, and managed all preclinical and clinical oncology-licensing activities. Prior to joining Merck, Dr. Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute from 1996 to 2009, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center from 2002 to 2009, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute from 2004 to 2009. Dr. Gilliland has a Ph.D. in Microbiology from UCLA and an M.D. from UCSF. He is board-certified in Internal Medicine and had his Fellowship training in Hematology and Oncology, each at Harvard Medical School.

What is Dwight Gary Gilliland's net worth?: The estimated net worth of Dwight Gary Gilliland is at least $727,927.92 as of October 30th, 2017. Gilliland owns 3,501 shares of Laboratory Co. of America stock worth more than $727,928 as of April 23rd. This net worth approximation does not reflect any other assets that Gilliland may own. Learn More about Dwight Gary Gilliland's net worth.
How do I contact Dwight Gary Gilliland?: The corporate mailing address for Gilliland and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Dwight Gary Gilliland's contact information.
Has Dwight Gary Gilliland been buying or selling shares of Laboratory Co. of America?: Dwight Gary Gilliland has not been actively trading shares of Laboratory Co. of America during the last quarter. Most recently, Dwight Gary Gilliland sold 500 shares of the business's stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $302.26, for a transaction totalling $151,130.00. Learn More on Dwight Gary Gilliland's trading history.
Who are Laboratory Co. of America's active insiders?: Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Brian Caveney (EVP), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.
Are insiders buying or selling shares of Laboratory Co. of America?: During the last year, insiders at the medical research company sold shares 14 times. They sold a total of 66,701 shares worth more than $14,419,280.01. The most recent insider tranaction occured on April, 1st when COO Mark S Schroeder sold 6,477 shares worth more than $1,407,387.33. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.
Information on this page was last updated on 4/1/2024.

Dwight Gary Gilliland Insider Trading History at Laboratory Co. of America

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/15/2021	Sell	500	$302.26	$151,130.00
10/30/2017	Sell	971	$153.52	$149,067.92	3,501

Dwight Gary Gilliland Buying and Selling Activity at Laboratory Co. of America

Laboratory Co. of America Company Overview

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Today's Range

Now: $207.92

$204.31

$210.63

50 Day Range

MA: $212.94

$199.44

$228.11

2 Week Range

Now: $207.92

$174.20

$234.09

Volume

925,306 shs

Average Volume

738,850 shs

Market Capitalization

$17.49 billion

P/E Ratio

44.52

Dividend Yield

1.43%

Beta

1.01